J&J Maintains Strategy For Biosimilar Remicade As Inflectra Nears
Executive Summary
The pharma is confident in its current discounting to protect Remicade market share in the US – it still plans to focus on a strategy involving bundling and relying on brand loyalty.
You may also be interested in...
Actelion Could Succumb To Big Pharma's Charms
News that Europe’s largest biotech Actelion is in preliminary discussions with Johnson & Johnson about a transaction has been viewed favourably by investors, and could see the return of mega-merger activity to other big pharma companies.
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.
Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Norwegian single-transition study would not satisfy agency's requirements for demonstrating interchangeability but could boost patient confidence in general concept of switching between reference product and biosimilar.